Dear Editor,

Hidradenitis suppurativa (HS) is a chronic, recurrent, debilitating inflammatory skin disease. It has a heterogeneous clinical presentation regardless of disease severity [1]. Therefore, different phenotypes are thought to exist which might differ in their pathogenesis and prognosis and which will likely benefit from different treatment modalities.

Based on clinical experience, a set of six phenotypes has been proposed in this journal: regular, frictional furunculoid, scarring folliculitis, conglobata, ectopic and syndromic [2]. However, our continued clinical experience suggested that the ectopic and syndromic types do not have specific clinical features and could be categorized as one of the other phenotypes. Here, we present the prevalence and patient characteristics of these phenotypes in a population of 935 Dutch HS patients participating in our HS registry at the Department of Dermatology of the Erasmus University Medical Center and its affiliated DermaHaven. All patients included in the study were diagnosed with HS according to the criteria of the European S1 guideline [3]. To help the phenotype designation in daily practice, we included a flowchart (Fig. 1) and prototypical clinical pictures of the phenotypes (available at www.karger.com/doi/10.1159/000518965). The need for ethical approval was waived by the Medical Research Eth-

Fig. 1. Flowchart to determine HS phenotypes in patients with diagnosed HS.
After descriptive statistical analysis, several noticeable differences between phenotypes became apparent (Table 1). The regular type was the most common variant (75.9%), followed by frictional furunculoid (10.3%), scarring folliculitis (7.2%) and the conglobata phenotype (6.6%). The conglobata variant was the only phenotype with a male predominance (71%). All phenotypes with specific clinical characteristics (i.e., frictional furunculoid, scarring folliculitis and conglobata) tended to have an earlier age of onset (respective median ages of 17.5, 17 and 16 years) compared to the regular type (median age of 20 years). Patients with the frictional furunculoid type had the

### Table 1. Patient characteristics per phenotype

|                                | All patients | Regular       | Frictional furunculoid | Scarring folliculitis | Conglobata     |
|--------------------------------|--------------|---------------|------------------------|-----------------------|----------------|
| Patients, n                    | 935 (100%)   | 710 (75.9%)   | 96 (10.3%)             | 67 (7.2%)             | 62 (6.6%)      |
| **Gender, n**                  |              |               |                        |                       |                |
| Female                         | 656 (70.2%)  | 508 (71.5%)   | 76 (79.2%)             | 54 (80.6%)            | 18 (29.0%)     |
| Male                           | 279 (29.8%)  | 202 (28.5%)   | 20 (20.8%)             | 13 (19.4%)            | 44 (71.0%)     |
| Missing                        | 0            | 0             | 0                      | 0                     | 0              |
| **Age of onset, years**        |              |               |                        |                       |                |
| Median                         | 19.0         | 20.0          | 17.5                   | 17.0                  | 16.0           |
| IQR (Q1, Q3)                   | 15.0, 27.0   | 15.0, 28.0    | 14.0, 27.0             | 14.0, 22.0            | 14.0, 19.0     |
| Missing                        | 195 (20.9%)  | 150 (21.1%)   | 22 (22.9%)             | 12 (17.9%)            | 11 (17.7%)     |
| **Family history, n**          |              |               |                        |                       |                |
| Yes (1st/2nd)                  | 291 (51.2%)  | 226 (52.3%)   | 30 (52.6%)             | 18 (43.9%)            | 17 (44.7%)     |
| No                             | 277 (48.8%)  | 206 (47.7%)   | 27 (47.4%)             | 23 (56.1%)            | 21 (55.3%)     |
| Missing/unknown                | 367 (39.3%)  | 278 (39.2%)   | 39 (40.6%)             | 26 (38.8%)            | 24 (38.7%)     |
| **BMI**                        |              |               |                        |                       |                |
| Median                         | 27.76        | 27.15         | 33.53                  | 29.51                 | 26.25          |
| IQR (Q1, Q3)                   | 24.34, 31.97 | 23.73, 31.28 | 29.08, 37.33           | 26.59, 32.42          | 23.22, 29.65  |
| Missing                        | 123 (13.1%)  | 100 (14.1%)   | 6 (6.3%)               | 4 (6%)                | 13 (21%)       |
| **Smoking status, n**          |              |               |                        |                       |                |
| Yes/Quit                       | 556 (73.0%)  | 403 (70.3%)   | 56 (75.7%)             | 52 (86.7%)            | 45 (81.8%)     |
| No                             | 206 (27.0%)  | 170 (29.7%)   | 18 (24.3%)             | 8 (13.3%)             | 10 (18.2%)     |
| Missing                        | 173 (18.5%)  | 137 (19.3%)   | 22 (22.9%)             | 7 (10.4%)             | 7 (11.3%)      |
| **IHS4**                       |              |               |                        |                       |                |
| Median                         | 3.0          | 3.0           | 4.0                    | 3.0                   | 5.0            |
| IQR (Q1, Q3)                   | 1.0, 8.0     | 1.0, 7.0      | 1.0, 12.0              | 0.0, 7.0              | 1.0, 14.25     |
| Missing                        | 32 (3.4%)    | 23 (3.2%)     | 1 (1%)                 | 4 (6%)                | 4 (6.5%)       |
| **Hurley stage, n**            |              |               |                        |                       |                |
| I                              | 508 (54.9%)  | 375 (53.2%)   | 64 (68.1%)             | 44 (67.7%)            | 25 (41.0%)     |
| II                             | 350 (37.8%)  | 284 (40.3%)   | 20 (21.3%)             | 20 (30.8%)            | 26 (42.6%)     |
| III                            | 67 (7.3%)    | 46 (6.5%)     | 10 (10.6%)             | 1 (1.5%)              | 10 (16.4%)     |
| Missing                        | 10 (1.1%)    | 5 (0.7%)      | 2 (2.1%)               | 2 (2%)                | 1 (1.5%)       |
| **Comorbidities**              |              |               |                        |                       |                |
| Crohn’s disease                | 23 (3.0%)    | 20 (3.5%)     | 1 (1.3%)               | 2 (3.5%)              | 0 (0%)         |
| Ulcerative colitis             | 11 (1.4%)    | 9 (1.6%)      | 1 (1.3%)               | 1 (1.8%)              | 0 (0%)         |
| SpA                            | 9 (1.2%)     | 3 (0.5%)      | 2 (2.5%)               | 1 (1.8%)              | 3 (5.6%)       |
| RA                             | 27 (3.5%)    | 19 (3.3%)     | 3 (3.8%)               | 2 (3.5%)              | 3 (5.6%)       |
| Missing                        | 168 (18.0%)  | 134 (18.9%)   | 16 (16.7%)             | 10 (14.9%)            | 8 (12.9%)      |

BMI, body mass index; IHS4, International Hidradenitis Suppurativa Severity Score System; SpA, spondyloarthritis; RA, rheumatoid arthritis; IQR, interquartile range; Q, quartile.

ics Committee of the Erasmus University Medical Center (MEC 2016-426).

Distinct Clinical Phenotypes in Hidradenitis Suppurativa
highest body mass index (median of 33.5 vs. 27.2 in the regular group). The distinct phenotypes also demonstrated a higher prevalence of smoking when compared to the regular type, most notably in the scarring folliculitis and conglobata variants (86.7 and 81.8 vs. 70.3%). Patients with the conglobata phenotype tended to have more severe HS according to the International Hidradenitis Suppurativa Severity Score System and Hurley stage, this in contrast to the scarring folliculitis phenotype which yielded the mildest cases. Interestingly, a positive family history of HS did not differ between the proposed phenotypes. Concomitant auto-inflammatory diseases were reported in 9.1% (70 of 767) of the patients in the registry. The frequency of spondyloarthritis and rheumatoid arthritis was highest in the conglobata phenotype while inflammatory bowel disease was not reported in this phenotype.

A strength of this study is that these phenotypes are based on extensive clinical experience and not solely on analysis of a data set lacking important clinical parameters [4]. The clinical characteristics and phenotypes can be used in future research such as genome-wide association studies. Furthermore, linking the phenotype and genotype could pave the way for a more tailor-made approach for future HS treatment options.

Key Message

Hidradenitis suppurativa can be stratified in different distinct clinical phenotypes, each possibly warranting specific treatment.

References

1 Sabat R, Jemec GBE, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020 Mar;6(1):18.
2 Van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S23–6.
3 Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619–44.
4 Van Straalen KR, Verhagen T, Horváth B, Ardon C, Vossen ARJV, Driessen R, et al. Poor interrater reliability of hidradenitis suppurativa phenotypes. J Am Acad Dermatol. 2018 Sep;79(3):577–8.

Statement of Ethics

Written informed consent to use the photos for publication was obtained from each patient. The need for ethical approval was waived by the Medical Research Ethics Committee of the Erasmus University Medical Center (MEC 2016-426).

Conflict of Interest Statement

Koen Dudink reports no conflicts of interest. Pim Aarts reports no conflicts of interest. Christine B. Ardon reports no conflicts of interest. Sterre B.L. Koster reports no conflicts of interest. Jonathan F. van den Bosch reports no conflicts of interest. Errol P. Prens received honoraria from AbbVie, Amgen, Celgene, Janssen, Galderma, Novartis and Pfizer for participation as a speaker and serving on advisory boards and also received investigator-initiated grants (paid to the Erasmus MC) from AbbVie, AstraZeneca, Janssen and Pfizer. Hessel H. van der Zee received honoraria from AbbVie, Galderma, Novartis and InflaRX for participation as a speaker and serving on advisory boards.

Funding Sources

There are for this study no relevant funding sources to declare.

Author Contributions

All authors have significant contribution to conceptualizing, writing and editing this paper. They have agreed to designate Koen Dudink as the primary correspondent with the editorial office to review the edited typescript and proof, and to make decisions regarding release of information in the paper.